Segall Bryant & Hamill LLC Makes New Investment in Guardant Health, Inc. $GH

Segall Bryant & Hamill LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 193,325 shares of the company’s stock, valued at approximately $10,061,000. Segall Bryant & Hamill LLC owned 0.16% of Guardant Health at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC grew its position in Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Allworth Financial LP boosted its position in shares of Guardant Health by 358.4% in the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after buying an additional 552 shares during the period. SVB Wealth LLC purchased a new position in shares of Guardant Health during the first quarter valued at $54,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Guardant Health during the second quarter valued at $62,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director owned 851 shares of the company’s stock, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 313,161 shares of company stock worth $18,996,062 over the last three months. Corporate insiders own 6.10% of the company’s stock.

Analyst Ratings Changes

GH has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. Scotiabank upped their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a research note on Thursday, July 31st. Piper Sandler increased their target price on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Leerink Partners boosted their price target on shares of Guardant Health from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Finally, Mizuho set a $100.00 price target on shares of Guardant Health in a research note on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.14.

Guardant Health Stock Performance

Shares of GH opened at $105.42 on Monday. The firm has a market cap of $13.29 billion, a PE ratio of -32.84 and a beta of 1.56. The firm’s 50 day moving average price is $74.94 and its 200 day moving average price is $58.76. Guardant Health, Inc. has a twelve month low of $29.91 and a twelve month high of $110.00.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.88) EPS. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.